At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Su Pin Choo, MBBS, MRCP(UK), FAMS, from the National Cancer Centre Singapore, Singapore, discusses the development of immunotherapy for patients with hepatocellular carcinoma (HCC), including early promising clinical data with nivolumab, a programmed cell death-1 (PD-1) antibody.
Immunotherapy for hepatocellular carcinoma
25th May 2016
Oncology
Please rate the quality of this content
We are sorry that this content was not interesting for you!
Let us improve this content!
Tell us how we can improve this content?